Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach.

Autor: Iniesta‐Navalón, C, Franco‐Miguel, JJ, Gascón‐Cánovas, JJ, Rentero‐Redondo, L
Předmět:
Zdroj: HIV Medicine; May2015, Vol. 16 Issue 5, p273-279, 7p
Abstrakt: Objectives The aim of the study was to determine the prevalence of potential clinically significant drug interactions ( CSDIs) in HIV-positive individuals and to identify associated risk factors. Methods A cross-sectional study was conducted including all HIV-infected out-patients attending the Pharmacy Service of a regional reference hospital in Murcia, south-eastern Spain. The complete treatment was screened for possible CSDIs using the Spanish College of Pharmacists' online software resource, bot. Additionally, the severity level of the CSDIs involving antiretroviral ( ARV) drugs was compared with that established in the specific antiretroviral database InteraccionesHIV.com. Multivariate logistic regression was used to identify associated risk factors. Results Two hundred and sixty-eight patients were included in the study. A total of 292 potential drug interactions were identified, of which 102 (34.9%) were CSDIs, of which 52.9% involved ARV drugs. Seven therapeutic drug classes were involved in 75% of CSDIs (protease inhibitors, benzodiazepines, nonsteroidal anti-inflammatory drugs, nonnucleoside reverse transcriptase inhibitors, corticosteroids, antithrombotics and proton pump inhibitors). Factors independently associated with CSDIs were treatment with more than five drugs [odds ratio ( OR) 15.1; 95% confidence interval ( CI) 6.3-36.2], and treatment with a protease inhibitor ( OR 5.3; 95% CI 2.4-11.74). Conclusions The findings of this study suggest that the prevalence of clinically relevant drug−drug interactions is high in HIV-infected patients, and could represent a major health problem. Awareness, recognition and management of drug interactions are important in optimizing the pharmaceutical care of HIV-infected patients and helping to prevent adverse events and/or loss of efficacy of the drugs administered. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Nepřihlášeným uživatelům se plný text nezobrazuje